Abdel-Hakeem, Mohamed S.
Manne, Sasikanth
Beltra, Jean-Christophe
Stelekati, Erietta
Chen, Zeyu
Nzingha, Kito
Ali, Mohammed-Alkhatim
Johnson, John L.
Giles, Josephine R.
Mathew, Divij
Greenplate, Allison R.
Vahedi, Golnaz
Wherry, E. John http://orcid.org/0000-0003-0477-1956
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (AI155577, AI105343, AI115712, AI117950, AI108545, AI082630 and CA210944)
Article History
Received: 4 May 2020
Accepted: 10 June 2021
First Online: 26 July 2021
Change Date: 29 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-021-01057-2
Competing interests
: E.J.W. is a member of the Parker Institute for Cancer Immunotherapy. E.J.W. has consulting agreements with and/or is on the scientific advisory board for Merck, Marengo Therapeutics, Janssen, Related Sciences, Synthekine and Surface Oncology. E.J.W. is a founder of Surface Oncology and Arsenal Biosciences. E.J.W. has a patent licensing agreement on the PD-1 pathway with Roche/Genentech. The remaining authors declare no competing interests.